UPDATE 1-Bristol-Myers lung cancer delay slams shares, keeps Merck in lead

New YORK, Jan 20 (Reuters) - Bristol-Myers Squibb Co

shares fell 11 percent on Friday following Thursday's

announcement that it would not seek accelerated approval of its

immunotherapy drug...

Read more